J45.01 (ATCC® CRL-1990)

Organism: Homo sapiens, human  /  Cell Type: T lymphocyte  /  Tissue: peripheral blood  /  Disease: acute T cell leukemia

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue peripheral blood
Cell Type T lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease acute T cell leukemia
Gender male
Storage Conditions liquid nitrogen vapor phase
Derivation
CD45 deficient cells were isolated using a fluorescence activated cell sorter, and cloned by limiting dilution.
The Jurkat cell line was established from the peripheral blood of a 14 year old boy by Schneider et al., and was originally designated JM.
The line was isolated after gamma irradiation of E6-1 followed by lysis of CD45 positive cells with the GAP 8.3 monoclonal antibody (see ATCC HB-12) and complement.
Clinical Data
The Jurkat cell line was established from the peripheral blood of a 14 year old boy by Schneider et al.
male
Antigen Expression
CD2 +; CD3 +; CD28 +; CD45 -
Receptor Expression
T cell antigen receptor
Genes Expressed
produce interleukin 2 (IL-2) in response to calcium ionophores and phorbol esters
Cellular Products
produce interleukin 2 (IL-2) in response to calcium ionophores and phorbol esters
Comments
The J45.01 cell line is a CD45 deficient variant of the E6-1 clone of Jurkat (ATCC TIB-152).
CD45 deficient cells were isolated using a fluorescence activated cell sorter, and cloned by limiting dilution.
The cells express the T cell antigen receptor (TCR, CD3), CD2 and CD28 at levels comparable to the parental line, but only 5 to 8% as much CD45.
Loss of CD45 diminishes TCR - CD2 signal transduction, thus the cells are inducible for interleukin 2 (IL-2) production with calcium ionophores and phorbol esters, but not with TCr or CD2 stimulation.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 105 cells/mLand maintain between 1 X 105 and 1 X 106 cells/mL.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage Temperature: Liquid nitrogen vapor phase
Culture Conditions
Temperature: 37°C
Name of Depositor GA Koretsky
References

Koretzky GA, et al. Tyrosine phosphatase CD45 is required for T-cell antigen receptor and CD2-mediated activation of a protein tyrosine kinase and interleukin 2 production. Proc. Natl. Acad. Sci. USA 88: 2037-2041, 1991. PubMed: 1672451

Schneider U, et al. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer 19: 621-626, 1977. PubMed: 68013

Ronald Wange, personal communication

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Koretzky GA, et al. Tyrosine phosphatase CD45 is required for T-cell antigen receptor and CD2-mediated activation of a protein tyrosine kinase and interleukin 2 production. Proc. Natl. Acad. Sci. USA 88: 2037-2041, 1991. PubMed: 1672451

Schneider U, et al. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer 19: 621-626, 1977. PubMed: 68013

Ronald Wange, personal communication